Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 22:13:10721-10727.
doi: 10.2147/OTT.S269983. eCollection 2020.

Human La Protein: An RNA-Binding Protein Involved in Ovarian Cancer Development and Multidrug Resistance

Xuan Huang  1 , Jing Tang  1
Affiliations
Review

Human La Protein: An RNA-Binding Protein Involved in Ovarian Cancer Development and Multidrug Resistance

Xuan Huang et al. Onco Targets Ther. .

Abstract

Multidrug resistance is the main cause of chemotherapy failure and death in patients with advanced ovarian cancer. Drug resistance is a problem that must be solved to improve the survival rate of patients with advanced ovarian cancer. The RNA-binding protein La and the La-related protein family are highly expressed in various malignant tumors, including ovarian cancer. This article reviews the mechanisms of La protein in tumorigenesis, development, and drug resistance. High La protein expression in tumor cells promotes tumor proliferation, invasion, and migration; disrupts cell cycle; and inhibits tumor cell apoptosis caused by chemotherapeutic drugs through various pathways, resulting in chemotherapy resistance in ovarian cancer. Further study of the role of La protein in ovarian cancer multidrug resistance may be conducive to the development of human La protein-specific inhibitors that suppress ovarian cancer drug resistance.

Keywords: La protein; Sjögren’s syndrome antigen B; chemotherapy drug resistance; multidrug resistance; ovarian cancer; ovarian cancer stem cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest for this work.

Figures

Figure 1
Figure 1
Domain organizations among La protein and La-related protein 1 (LARP1).
Figure 2
Figure 2
Roles of La protein as a tumor promoter and multidrug resistance agent.
See this image and copyright information in PMC

References

    1. Webb PM, Jordan SJ. Epidemiology of Epithelial Ovarian Cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14. - PubMed
    1. Holmes D. Ovarian cancer: beyond resistance. Nature. 2015;527(7579):217. - PubMed
    1. Lupia M, Cavallaro U. Ovarian cancer stem cells: still an elusive entity? Mol Cancer 2017;16(1):64. - PMC - PubMed
    1. Moore KN, Martin LP, Omalley DM, et al. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol. 2018;14(2):123–136. - PubMed
    1. Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM. A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer. J Med Oncol. 2017;34(6):103. - PubMed